预约演示
Crossbow raises Series A funds to develop cancer antibodies
2023-07-12
疫苗免疫疗法
Crossbow Therapeutics will use the funds to develop therapies to treat cancer. Credit: crystal light via Shutterstock.com.
Crossbow Therapeutics has raised Series A funds worth $80m to develop acancerlass of antibody treatments for cancer.
Crossbow Therapeuticszer Ventures led the funding round, with Polaris Partners, BVF Partners and Eli Lilly ancancerany among others taking part.
ReportsLOA and PTSR Model - Vaccine For Oncology in Colorectal Cancer GlobalData
ReportsLOA and PTSR Model - Gene Therapy To Target Lewis Y Antigen For Lung Cancer in Lung Cancer GlobalData
View allCompanies IntelligenceEli Lilly and CoPolariColorectal Cancer Partners LPCrossbow CorpPfizer Ventures LLCView all
Proceeds will be used to progress the development of new therapies that act on peptide-loaded major histocompatibility complexes (pMHCs) present on cancer cells.
To target pMHCs, these therapies will leverage antiLewis Y Antigentate Lung CancerptorLung Cancertics).
The company will identify, validate and select the most promising cancer-specific targets, then create TCR-mimetic antibodies that have greater levels of cancer cell affinity and specificity.
Such TCR-mimetics will be merged with off-the-shelf T-cell engagers and immunotherapies to create tumour-bolt (T-Bolt) molecules.cancer
These T-Bolts can be tailored to treat a variety of cancers.T-cell receptors
“The influx of additional capital enables us to scale our efforts to build an arsenal of TCR-mimettumoured immunotherapies designed to overcome the limitations of current treatments.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
-提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。